Suppression of the STAT3/MYC/MCL-1 pathway by the fixed Jianpi Huoxue Formula relieves early biochemical abnormalities in liver fibrosis

doi:10.4254/wjh.122262

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(2)

(0)

(33)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Aug 27, 2026; 18(8): 122262
Published online Aug 27, 2026. doi: 10.4254/wjh.122262

Table 2 Baseline characteristics of the included patients

Variable	JHF group (n = 20)	Control group (n = 20)	P value
Sex (male/female)	10:10	14:6	0.167
Age	36.25 ± 12.53	39.5 ± 13.89	0.442
Etiology			0.673
HLD	17	15
HBV	2	4
Autoimmune hepatitis	1	1
Pre-treatment
ALT (U/L)	66.04 ± 11.72	67.09 ± 12.43	0.786
TBIL (μmol/L)	61.49 ± 18.97	64.29 ± 24.26	0.687
PT (s)	13.75 ± 1.72	13.16 ± 1.46	0.248
HA (ng/mL)	187.38 ± 67.98	171.84 ± 49.02	0.412
LN (ng/mL)	441.74 ± 455.09	404.33 ± 404.86	0.785
PIIINP (ng/mL)	157.95 ± 57.07	153.03 ± 82.53	0.828
CIV (ng/mL)	89.19 ± 30.76	65.75 ± 56.59	0.112
Liver stiffness (kPa)	14.12 ± 4.43	14.50 ± 5.02	0.802
Shear wave velocity (m/s)	2.10 ± 0.33	2.13 ± 0.39	0.760
Post-treatment
ALT (U/L)	30.65 ± 11.63	40.00 ± 9.27	0.008
TBIL (μmol/L)	22.47 ± 9.73	31.01 ± 10.33	0.032
PT (s)	11.25 ± 1.08	12.28 ± 1.80	0.033
HA (ng/mL)	132.09 ± 66.54	171.74 ± 52.42	0.043
LN (ng/mL)	86.44 ± 27.76	167.35 ± 178.08	0.052
PIIINP (ng/mL)	15.87 ± 5.04	76.34 ± 80.59	0.002
CIV (ng/mL)	21.83 ± 12.67	39.44 ± 32.35	0.029
Liver stiffness (kPa)	12.50 ± 3.61	13.60 ± 3.93	0.367
Shear wave velocity (m/s)	1.98 ± 0.28	2.08 ± 0.29	0.315

JHF: Jianpi Huoxue Formula; HLD: Hepatolenticular degeneration; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; TBIL: Total bilirubin; PT: Prothrombin time; HA: Hyaluronic acid; PIIINP: Procollagen N-terminal peptide; CIV: Type IV collagen; LN: Laminin.

Full Size Table

Citation: Huang L, Wu CG, Zhu TF, Li QL, Yu QS, Zhang Q, Shen Y. Suppression of the STAT3/MYC/MCL-1 pathway by the fixed Jianpi Huoxue Formula relieves early biochemical abnormalities in liver fibrosis. World J Hepatol 2026; 18(8): 122262
URL: https://www.wjgnet.com/1948-5182/full/v18/i8/122262.htm
DOI: https://dx.doi.org/10.4254/wjh.122262

Huang L, Wu CG, Zhu TF, Li QL, Yu QS, Zhang Q, Shen Y. Suppression of the STAT3/MYC/MCL-1 pathway by the fixed Jianpi Huoxue Formula relieves early biochemical abnormalities in liver fibrosis. World J Hepatol 2026; 18(8): 122262 [DOI: 10.4254/wjh.122262]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.